Ensoma Announces $85 Million Financing And Agreement To Acquire Twelve Bio To Advance Portfolio Of In Vivo Engineered Cellular Medicines
Amount Raised
$85 Million
Round Type
Funding Round
BostonBiotechnologyHealth CareInvestors
Description
Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the completion of an $85 million financing. Proceeds will enable Ensoma to advance the development of its EngeniousTM in vivo engineered cell therapy platform and accelerate its pipeline of genomic medicines for immuno-oncology and other therapeutic applications. The company also announced it has entered into a definitive agreement to acquire Twelve Bio ApS, a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas technology.
Quick answer
Ensoma raised $85 Million in a Funding Round round, dated January 5, 2023. Investors: Mirae Asset, Solasta Ventures, Catalio Capital Management, Qatar Investment Authority, Alexandria Venture Investments, Takeda Ventures, Viking Global Investors and Cormorant Asset Management. Ensoma is based in Boston, Massachusetts, United States.
- How much did Ensoma raise?
- Ensoma raised $85 Million in a Funding Round round on January 5, 2023.
- Who invested in Ensoma?
- Mirae Asset, Solasta Ventures, Catalio Capital Management, Qatar Investment Authority, Alexandria Venture Investments, Takeda Ventures, Viking Global Investors and Cormorant Asset Management are named as investors in this round.
- What does Ensoma do?
- Ensoma is developing potentially curative medicines for genetic diseases, immune disorders and cancer through in vivo hematopoietic stem cells (HSCs) engineering.
- Where is Ensoma based and how big is it?
- Ensoma is based in Boston, Massachusetts, United States. Fundz records about 101 employees.
- Who are the decision-makers at Ensoma?
- Fundz holds 2 contacts at Ensoma. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Ensoma that raised within 45 days of this round, from Fundz verified event records.
- Pathos AI raised $20M on February 17, 2023.
- U.S. Renal Care raised $3.1M (Seed) on February 16, 2023.
- Previa Medical raised $2.2M (Seed) on February 16, 2023.
- Alpha Cognition raised $1.8M (Seed) on February 16, 2023.
- Rhaeos raised $11M (Series A) on February 16, 2023.
- Codagenix raised $25M (Series B) on February 15, 2023.
Who to call at Ensoma, and when
A new round usually means Ensoma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Ensoma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ensoma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ensoma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ensoma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Ensoma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.